mitogen-activated protein kinase 1 interacting protein 1 likeGenealiases: C14orf32 · MISS · c14_5346
Q-omics provides the consensus-scored MAPK1IP1L profile across patient tissues and cancer cell-line models. MAPK1IP1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAPK1IP1L is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MAPK1IP1L RNA expression shows 20,504 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where MAPK1IP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK1IP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK1IP1L survival associations across molecular data types. MAPK1IP1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK1IP1L RNA expression–survival associations across cancer types. High MAPK1IP1L expression shows unfavorable associations in ACC, UVM, LIHC and LUAD, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAPK1IP1L RNA expression.
This table summarizes MAPK1IP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MAPK1IP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK1IP1L shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in HNSC, LIHC and CHOL. The KIRC box plot shows higher MAPK1IP1L RNA expression in normal versus tumor tissue (log2 FC = −0.547, t-test p < 0.001).
This table shows molecular features associated with MAPK1IP1L in patient tissues and cancer cell lines. In patient samples, MAPK1IP1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK1IP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
